We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » APP Benefits From Baxter’s Heparin Troubles
APP Benefits From Baxter’s Heparin Troubles
March 4, 2008
APP Pharmaceuticals says it is prepared to meet U.S. demand for multidose vials of therapeutic heparin after production difficulties for Baxter’s competing product sparked concerns of drug shortages and led to intense congressional scrutiny of the FDA, including a call for the resignation of Commissioner Andrew von Eschenbach.